Patents Assigned to LEONHARDT VENTURES LLC
-
Patent number: 11819688Abstract: A skin regeneration therapy combining precise bioelectric signals, light, and biologics for skin treatment and regeneration. Precise bioelectric signals give clear instructions to the stimulated cell DNA/RNA to produce specific regenerative proteins on demand. Bioelectric signals give clear instructions to cell membranes on what to let in and what to let out and serve as an equivalent or surrogate of environmental stimuli to cause a cell action in response.Type: GrantFiled: July 6, 2021Date of Patent: November 21, 2023Assignee: Leonhardt Ventures LLCInventors: Howard J. Leonhardt, Jorge Genovese
-
Patent number: 11691007Abstract: Described is a method of treating a subject diagnosed with cancer, breast cancer, bone cancer, lung cancer, osteoporosis, multiple myeloma, and a combination of any thereof by applying a bioelectric signal or signals that upregulate the expression of Osteoprotegerin (“OPG”) and thus beneficially effect the subject's OPG/RANKL/RANK pathway.Type: GrantFiled: June 26, 2020Date of Patent: July 4, 2023Assignee: Leonhardt Ventures LLCInventors: Howard J. Leonhardt, Jorge Genovese
-
Patent number: 11471686Abstract: Described is a low voltage, pulsed electrical stimulation device for controlling expression of klotho, a useful protein, by tissues. Also described are methods of enhancing expression of klotho in cells.Type: GrantFiled: March 13, 2019Date of Patent: October 18, 2022Assignee: Leonhardt Ventures LLCInventor: Howard J. Leonhardt
-
Patent number: 11446488Abstract: Described is a low voltage, pulsed electrical stimulation device for controlling expression of klotho, a useful protein, by tissues. Also described are methods of enhancing expression of klotho in cells and treating a subject's kidneys.Type: GrantFiled: February 24, 2020Date of Patent: September 20, 2022Assignee: Leonhardt Ventures LLCInventor: Howard J. Leonhardt
-
Patent number: 11433231Abstract: Described is a low voltage, pulsed electrical stimulation device for controlling expression of sonic hedgehog (“Shh”), a useful protein, by tissues. Also described are methods of enhancing expression of sonic hedgehog in cells, particularly a method of stimulating the expression and/or release of Shh in a cell having a gene encoding Shh, wherein the method includes applying a bioelectric signal of less than 50 Hz (e.g., 5 Hz, 10 Hz, or 20 Hz) at a pulse width duration of, e.g., 1 ms, to the cell (e.g., directly, indirectly, or wirelessly), and wherein the amount of Shh expression enhanced by this bioelectric signal is greater than that seen with a prior art bioelectric muscle stimulation or bioelectric muscle contraction alone as may be determined by, e.g., by an analysis of the upregulation of mRNA level/GAPDH fold gene expression in the cell.Type: GrantFiled: April 13, 2020Date of Patent: September 6, 2022Assignee: LEONHARDT VENTURES LLCInventor: Howard J. Leonhardt
-
Patent number: 11185691Abstract: Described are a system and method that “reads” cancer tumors real time and custom delivers individualized bioelectric therapy to the patient. For example, the system reads a cancer tumor, and based upon this read, delivers to the subject “a confounding signal” to jam communication within that tumor. A cancer tumor may change its communication patterns and the therapy is designed to change with these patterns, attempting to always jam the relevant communication signaling pathway. The described system includes parameters not tied to communication jamming, which should also be customized to induce apoptosis to the cancer tumor. Such parameters include signals for starving a cancer tumor of blood supply and signals for changing the cancer tumor's surface proteins and/or charge so that the immune system attacks the cancer tumor.Type: GrantFiled: September 20, 2018Date of Patent: November 30, 2021Assignee: LEONHARDT VENTURES LLCInventors: Howard J. Leonhardt, Jorge Genovese
-
Patent number: 11167141Abstract: Described are a system and method that utilize bioelectric signaling to balance electrical potentials in a subject's body via neuro-hormonal circuit loops, to increase elasticity of the subject's arteries to promote protein release to dampen arterial blood pressure, and to change arterial electrical charges to reduce narrowing of the arteries. The described system is designed to localize and stimulate the fibers inside the vagus nerve without inadvertent stimulation of non-baroreceptive fibers causing side effects like bradycardia and bradypnea. The system also controls release of specific proteins known to lower blood pressures including tropoelastin (known to increase elasticity in the aorta and other peripheral blood vessels).Type: GrantFiled: September 20, 2018Date of Patent: November 9, 2021Assignee: LEONHARDT VENTURES LLCInventor: Howard J. Leonhardt
-
Patent number: 11110274Abstract: Described is a low voltage, pulsed electrical stimulation device for reducing inflammation in a subject, which can be useful in the treatment of concussions, traumatic brain injury, cancer, and so forth.Type: GrantFiled: September 20, 2018Date of Patent: September 7, 2021Assignee: LEONHARDT VENTURES LLCInventor: Howard J. Leonhardt
-
Patent number: 11052247Abstract: A skin regeneration therapy combining precise bioelectric signals, light, and biologics for skin treatment and regeneration. Precise bioelectric signals give clear instructions to the stimulated cell DNA/RNA to produce specific regenerative proteins on demand. Bioelectric signals give clear instructions to cell membranes on what to let in and what to let out and serve as an equivalent or surrogate of environmental stimuli to cause a cell action in response.Type: GrantFiled: September 12, 2018Date of Patent: July 6, 2021Assignee: LEONHARDT VENTURES LLCInventors: Howard J. Leonhardt, Jorge Genovese
-
Patent number: 10960206Abstract: Described is a low voltage, pulsed electrical stimulation device for controlling expression of, for example, follistatin, a muscle formation promotion protein, by tissues. Epicardial stimulation is especially useful for heart treatment. Follistatin controlled release is also useful for treating other ailments, such as erectile dysfunction, aortic aneurysm, and failing heart valves.Type: GrantFiled: November 14, 2017Date of Patent: March 30, 2021Assignee: LEONHARDT VENTURES LLCInventors: Howard J. Leonhardt, Jorge Genovese